Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome

Toxins (Basel). 2018 Apr 19;10(4):164. doi: 10.3390/toxins10040164.

Abstract

A lumbar sympathetic ganglion block (LSB) is a therapeutic method for complex regional pain syndrome (CRPS) affecting the lower limbs. Recently, LSB with botulinum toxin type A and B was introduced as a novel method to achieve longer duration of analgesia. In this study, we compared the botulinum toxin type A (BTA) with botulinum toxin type B (BTB) in performing LSB on patients with CRPS. LSB was performed with either BTA or BTB on patients with CRPS in their lower extremities. The length of time taken for patients to return to the pre-LSB pain score and the adverse effect of LSB with BTA/BTB were investigated. The median length of time taken for the patients to return to the pre-LSB pain score was 15 days for the BTA group and 69 days for the BTB group (P = 0.002). Scores on a visual analogue scale decreased in the patients of both groups, and no significant adverse effects were experienced. In conclusion, the administration of either BTA or BTB for LSB is a safe method to prolong the sympathetic blocking effect in patients with CRPS. BTB is more effective than BTA to prolong the sympathetic blocking effect in CRPS patients.

Keywords: botulinum toxin; complex regional pain syndrome; lumbar sympathetic ganglion block; pain.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Botulinum Toxins, Type A*
  • Complex Regional Pain Syndromes / drug therapy*
  • Female
  • Humans
  • Lumbar Vertebrae / innervation
  • Male
  • Middle Aged
  • Nerve Block*
  • Sympatholytics*
  • Young Adult

Substances

  • Sympatholytics
  • rimabotulinumtoxinB
  • Botulinum Toxins, Type A